CCCC

C4 Therapeutics is a clinical-stage protein-degradation company with no product revenue — the $35.9M FY2025 top line is entirely collaboration/license income (Betta Pharma, Merck KGaA, Roche) and it was flat YoY (+1.0%), so the headline P/S of 11.7x is not economically meaningful. What matters is that the company is pre-approval on everything: two clinical degraders (cemsidomide for multiple myeloma, CFT8919 for EGFR-L858R NSCLC, the latter partnered to Betta in Greater China) plus early inflammation/neuro discovery work off the TORPEDO platform. The 10-K is blunt that it has 'not generated any revenue from product sales,' expects losses 'for at least the next several years,' and carries a $738.7M accumulated deficit — this is a binary, catalyst-driven equity, not a fundamentals-driven one.

The reason this is a hold rather than an avoid is the balance sheet. There is zero debt, equity of $257M against just $102M of liabilities (0.40x), and current assets of $258M versus only $33M of current liabilities — the market cap of $420M is largely backed by liquidity, ascribing only a modest (~$170M) premium to the entire pipeline. The MD&A discloses a $125M gross October 2025 raise (with up to $225M more if warrants are exercised), so despite a ~$99M annual operating cash burn the company appears funded through its next set of clinical readouts. The cost of that funding, however, is visible in the 37.5% YoY jump in share count — dilution is the recurring tax shareholders pay here, and diluted EPS of -$1.27 sits on a much larger base than a year ago.